Kalkine Media reports that Australian-based biotech Actinogen Medical, announced the registration of final patient into its placebo-controlled phase 2 Xanamem trial called XanADu. Developed by Actinogen, Xanamem is an inhibitor of 11β-hydroxysteroid dehydrogenase, an...